AR and pachyonychia congenita: After head-to-head comparisons between the currently approved AR antagonist enzalutamide and ARCC-4 in different cell models of PC resistance, the antitumor efficacy of ARCC-4, evaluated by PSA expression reduction, induction of cell apoptosis, and AR-dependent cell proliferation inhibition, outperformed enzalutamide.